Cover Image
市場調查報告書

馬腦炎:開發中產品分析

Equine Encephalitis - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 229777
出版日期 內容資訊 英文 51 Pages
訂單完成後即時交付
價格
Back to Top
馬腦炎:開發中產品分析 Equine Encephalitis - Pipeline Review, H2 2016
出版日期: 2016年10月26日 內容資訊: 英文 51 Pages
簡介

馬腦炎是以蚊子為媒介的傳染病,特徵為造成人腦嚴重發炎。主要的症狀有突然的發熱和發冷、人體·關節的疼痛等。不同情況下腦炎有可能嚴重化,造成頭痛和喪失方向感、發抖、癲癇、麻痺狀態等。

本報告提供全球各國治療馬腦炎治療所用的開發中產品之開發情形相關分析,提供您產品開發·上市的最新趨勢,及臨床實驗各階段產品一覽,再加上主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

簡介

  • 調查範圍

馬腦炎概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品比較分析

馬腦炎:企業開發中的治療藥

馬腦炎:大學/機關研究中的治療藥

馬腦炎:開發中產品概況

  • 臨床階段的產品
  • 初期階段的產品

馬腦炎:企業開發中的產品

馬腦炎:大學/機關研究中的產品

馬腦炎的治療藥開發企業

  • Akshaya Bio Inc.
  • Altravax, Inc.
  • EpiVax, Inc.
  • Integrated BioTherapeutics, Inc.
  • Karyopharm Therapeutics, Inc.
  • Profectus BioSciences, Inc.

馬腦炎:治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

馬腦炎:最近的開發平台趨勢

馬腦炎:暫停中的計劃

馬腦炎:產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8579IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Equine Encephalitis - Pipeline Review, H2 2016, provides an overview of the Equine Encephalitis (Central Nervous System) pipeline landscape.

Equine encephalitis (EE) is mosquito transmitted disease that can cause severe inflammation of the brain (encephalitis) in humans. Symptoms include the sudden onset of fever, chills, body and joint aches. Infection can develop into severe encephalitis, resulting in headache, disorientation, tremors, seizures and paralysis. Permanent brain damage, coma and death may also occur in some cases. Approximately a third of patients who develop EE die, and many of those who survive have mild to severe brain damage.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Equine Encephalitis - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Equine Encephalitis (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Equine Encephalitis (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Equine Encephalitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Preclinical and Discovery stages are 8 and 3 respectively for Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 1, 2 and 1 molecules, respectively for Equine Encephalitis.

Equine Encephalitis (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Equine Encephalitis (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Equine Encephalitis (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Equine Encephalitis (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Equine Encephalitis (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Equine Encephalitis (Central Nervous System)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Equine Encephalitis (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Equine Encephalitis (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Equine Encephalitis Overview
  • Therapeutics Development
    • Pipeline Products for Equine Encephalitis - Overview
    • Pipeline Products for Equine Encephalitis - Comparative Analysis
  • Equine Encephalitis - Therapeutics under Development by Companies
  • Equine Encephalitis - Therapeutics under Investigation by Universities/Institutes
  • Equine Encephalitis - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Equine Encephalitis - Products under Development by Companies
  • Equine Encephalitis - Products under Investigation by Universities/Institutes
  • Equine Encephalitis - Companies Involved in Therapeutics Development
    • Akshaya Bio Inc.
    • Altravax, Inc.
    • EpiVax, Inc.
    • Integrated BioTherapeutics, Inc.
    • Karyopharm Therapeutics, Inc.
    • Profectus BioSciences, Inc.
  • Equine Encephalitis - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • DEF-201 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • equine encephalitis vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • equine encephalitis vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • equine encephalitis vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • imatinib mesylate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibodies for Equine Encephalitis and Chikungunya - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody for Venezuelan Equine Encephalitis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • nilotinib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TSI-GSD-104 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vaccine for Western Equine Encephalitis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • venezuelan equine encephalitis vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Venezuelan equine encephalitis vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • venezuelan equine encephalitis vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • verdinexor - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Westrern Equine Encephalitis Virus Vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Equine Encephalitis - Dormant Projects
  • Equine Encephalitis - Product Development Milestones
    • Featured News & Press Releases
      • Dec 09, 2015: Profectus BioSciences Receives $4.6 Million DOD Grant to Develop Vaccine for Western, Eastern, and Venezuelan Equine Encephalitis Viruses
      • Dec 09, 2015: Profectus BioSciences Receives $4.6 Million DOD Grant to Develop Vaccine for Western, Eastern, and Venezuelan Equine Encephalitis Viruses
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Equine Encephalitis, H2 2016
  • Number of Products under Development for Equine Encephalitis - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Equine Encephalitis - Pipeline by Akshaya Bio Inc., H2 2016
  • Equine Encephalitis - Pipeline by Altravax, Inc., H2 2016
  • Equine Encephalitis - Pipeline by EpiVax, Inc., H2 2016
  • Equine Encephalitis - Pipeline by Integrated BioTherapeutics, Inc., H2 2016
  • Equine Encephalitis - Pipeline by Karyopharm Therapeutics, Inc., H2 2016
  • Equine Encephalitis - Pipeline by Profectus BioSciences, Inc., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Equine Encephalitis - Dormant Projects, H2 2016

List of Figures

  • Number of Products under Development for Equine Encephalitis, H2 2016
  • Number of Products under Development for Equine Encephalitis - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Targets, H2 2016
  • Number of Products by Stage and Targets, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top